A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Exclusion Criteria

• •History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study.
• •History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
• •Any clinically important illness, medical/surgical procedure or trauma.
• •Clinically significant serious active and chronic infections.
• •Bacillus Calmette-Guérin vaccine within one year prior to signing the ICF.
• •Any abnormal laboratory values at the Screening Visit.
• •Any positive result on Screening for serum Hepatitis B surface antigen (HBsAg), anti-Hepatitis B core (HBc), hepatitis C antibody, or Human Immunodeficiency Virus (HIV).
• •Any cardiac abnormalities.
• •History of alcohol abuse or drug abuse.
• •Current smokers or those who have smoked or used nicotine products.
• •History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.
• •Clinical signs and symptoms consistent with COVID-19.
• •In addition, any of the following is regarded as a criterion for exclusion from the genetic research:
• •1. Previous bone marrow transplant
• •2. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection